


Ο ρόλος του Πνευμονολόγου στην προ και μετεγχειρητική φροντίδα του μη θωρακοχειρουργικού ασθενούς


▪ Μετεγχειρητική παρακολούθηση




Αντωνογιαννάκη Ελβίρα-Μαρκέλα
Επικουρική Επιμελήτρια Β'
Β' Πνευμονολογική Κλινική
ΕΚΠΑ, ΠΓΝ Αττικόν



Postoperative pulmonary complications



Postoperative pulmonary complications



Postoperative pulmonary complications

Risk factors

Anesthetic factors	Surgery factors	Patient factors
Anesthesia-induced atelectasis	Vascular surgeries	Age >65 and <6 ys
Positive fluid balance	Thoracic surgery (one lung ventilation)	ASA≥3
Blood transfusion 4 units or more	Upper abdominal surgery	COPD
Ventilatory settings (VT/Pplateau)	Neurosurgery	OSAS
General anesthesia	Orofacial and neck surgery	Preoperative Sp02
Use of nasogastric tube	Emergency surgery	CHF
Need for postoperative ventilation	Reoperation	Respiratory infection within a month
Long-acting muscle relaxants	Surgeries 3hr or more	Functional dependency
Intravenous vs inhalation anesthesia	Open vs laparoscopic	Smoker
Mask vs endotracheal tube		Family history of asthma/atopy
		Alcohol abuse
		PH
		Weight loss>10%
		Albumin <3.5g/dl
		Hb<10g/dl
		Impaired sensorium
		Abnormal chest x-ray
		BMI >27kg/m2

Postoperative pulmonary complications

Surgery factors

Point values assigned by each scoring system


	PRF risk index ^a [9]	Pneumonia risk index ^b [8]	ARISCAT PPC score [6]	SLIP [23 ^c]	UEPI [7 ^d]	PRF risk calculator ^c [45 ^e]
Cardiac	Excluded	Excluded	24	19 ^d	Excluded	1.32
Thoracic	21	14	24	16 ^e	1	1.96
Abdominal aortic aneurism	27	15		32 ^f	1	2.94 ^g
Upper abdominal	14	10	15		1	2.64
Neurosurgery	14	8			1	2.08
Neck	11	8				1.11 ^h
Peripheral vascular	14	3			1	
Urology						1.36
Other medium to very high risk surgery					1	
Duration of surgery						
2–3 h			16	Excluded		
>3 h			23	Inclusion criteria		
Emergency surgery	11	3	8	Excluded		0.56
General anaesthesia		4				

Postoperative pulmonary complications


Incidence-Mortality

- Risk incidence >20% in high risk procedures
- 19-59% after thoracic surgery
- 16-20% after upper abdominal surgery
- 0-5% after lower abdominal surgery
- Postoperative pulmonary complications mortality 10-25%


Sachdev J G et al, Surg Clin N Am, 2012
Canet J et al, Curr Opin Anesthesiol, 2013



Postoperative respiratory failure





Postoperative respiratory failure



Lindberg P et al, Acta Anesthesiol Scan, 1992

Postoperative respiratory failure


Lung mechanics




Reber A et al, Anaesthesia, 1998
Hedensternia G et al, Compr Physiology, 2012

Postoperative respiratory failure V/Q relationship

Supine + Anesthesia




Postoperative respiratory failure V/Q relationship



Tokics L et al, J Appl Physiol, 1996

Postoperative respiratory failure V/Q relationship



Tokics L et al, J Appl Physiol, 1996

Postoperative respiratory failure

Atelectasis

IV or inhalation anesthesia
Length of surgery
Type of surgery
Position of patient
Age
Body habitus
Lung disease
Surgical factors

Increased FiO₂
Low V/Q


Anesthetic agents
Duration of surgery
Decreased tidal volume

Compression

Gas Absorption


Impaired Surfactant

ATELECTASIS



Postoperative respiratory failure


Absorption atelectasis



Dantzker DR et al, J Appl Physiol, 1975


Postoperative respiratory failure

Muscle function



Postoperative respiratory failure


Muscle function



Postoperative respiratory failure


ARDS

- 1/3 pts with ARDS (mild-moderate) post-surgery
- Mean incidence after high risk procedures 5-7%




Postoperative respiratory failure

ARDS




Postoperative respiratory failure

ARDS



Postoperative respiratory failure

VILI (Ventilation Induced Lung Injury)




Sprung J et al, Ventilatory strategies during anesthesia, Cambridge Press, 2010

Postoperative respiratory failure

TRALI (Transfusion Acute Lung Injury)


- ARDS
- During or within 6 hrs of transfusion
- Exclusion clinical diagnosis



Kleinman et al, Transfusion, 2010

Postoperative respiratory failure

TRALI



Storch E et al, Blood, 2014

Postoperative pulmonary complications

Prevention - Intraoperative

- **Surgery parameters** [thoracoscopic/laparoscopic procedure, duration]
- **Ventilatory parameters** [accurate FiO_2 , avoid **atelectotauma** (PEEP, recruitment manoeuvres), avoid **barotrauma** (lung-protective ventilation)]
- **Anesthetic parameters** [neuroxial/regional/inhaled anesthesia, avoid overuse of opiates, reversal NM blockage agents]
- **Others parameters (fluids, transfusion)**

Postoperative pulmonary complications

Prevention – Postoperative

Adequate pain control
(epidural/non opiates)

Early mobilization

Non invasive ventilation
(CPAP/BIPAP/
high flow nasal therapy)


Physiotherapy

Methods to prevent postoperative pulmonary complications

Pulmonary rehabilitation


Postoperative respiratory failure

Oxygen therapy/Ventilatory Support



Continuous Positive Airway Pressure for Treatment of Postoperative Hypoxemia



A Randomized Controlled Trial



Squadrone J et al, JAMA, 2005

Effect of Noninvasive Ventilation on Tracheal Reintubation Among Patients With Hypoxemic Respiratory Failure Following Abdominal Surgery

A Randomized Clinical Trial



Jaber S et al, JAMA, 2016

Postoperative respiratory failure



High flow nasal therapy (HFNT)



Heated, humified mixture of air
and oxygen



30-60 L/min




Coligher E et al, AJRCCM, 2017

Postoperative respiratory failure

HFNT


Study or Subgroup	HFNC			Control			Weight	Risk Ratio M-H, Random, 95% CI
	Events	Total	Events	Total				
Brainard 2017	1	18	2	26	4.4%	0.72 [0.07, 7.38]		
Chen 2018	7	43	19	45	41.0%	0.39 [0.18, 0.82]		
Corley 2015	0	81	2	74	2.6%	0.18 [0.01, 3.75]		
Dhillon 2017	3	46	19	138	17.2%	0.47 [0.15, 1.53]		
Geng 2017	1	25	9	23	6.0%	0.10 [0.01, 0.75]		
Parke 2013	2	169	0	171	2.6%	5.06 [0.24, 104.59]		
Sun 2017	3	24	8	24	16.4%	0.38 [0.11, 1.25]		
Xu 2018	1	45	7	45	5.6%	0.14 [0.02, 1.11]		
Yu 2017	1	56	2	54	4.2%	0.48 [0.05, 5.16]		
Total (95% CI)	507		600	100.0%		0.38 [0.23, 0.61]		
Total events	19		68					
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 6.06$, df = 8 ($P = 0.64$); $I^2 = 0\%$								
Test for overall effect: $Z = 3.92$ ($P < 0.0001$)								




Postoperative respiratory failure

HFNT

Study or Subgroup	Experimental		Control		Weight	Risk Ratio M-H, Random, 95% CI
	Events	Total	Events	Total		
Brainard 2017	1	18	2	26	0.9%	0.72 [0.07, 7.38]
Dhillon 2017	4	46	12	138	4.1%	1.00 [0.34, 2.95]
Futier 2016	58	108	68	112	90.6%	0.88 [0.70, 1.11]
Sun 2017	1	24	2	24	0.9%	0.50 [0.05, 5.15]
Yu 2017	4	56	7	54	3.5%	0.55 [0.17, 1.78]
Total (95% CI)	252		354		100.0%	0.87 [0.70, 1.08]
Total events	68		91			
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 0.94$, df = 4 ($P = 0.92$); $I^2 = 0\%$						
Test for overall effect: $Z = 1.26$ ($P = 0.21$)						




Study or Subgroup	Experimental		Control		Weight	Risk Ratio M-H, Random, 95% CI
	Events	Total	Events	Total		
Chen 2018	1	43	4	45	23.7%	0.26 [0.03, 2.25]
Dhillon 2017	1	46	11	138	26.9%	0.27 [0.04, 2.06]
Futier 2016	2	108	3	112	35.0%	0.69 [0.12, 4.06]
Parke 2013	1	169	1	171	14.4%	1.01 [0.06, 16.05]
Yu 2017	0	56	0	54		Not estimable
Total (95% CI)	422		520		100.0%	0.45 [0.16, 1.29]
Total events	5		19			
Heterogeneity: $\tau^2 = 0.00$; $\chi^2 = 1.06$, df = 3 ($P = 0.79$); $I^2 = 0\%$						
Test for overall effect: $Z = 1.49$ ($P = 0.14$)						



Postoperative respiratory failure

HFNT




Patients after abdominal surgery **without hypoxemia**


Futier et al, Crit Care Med, 2016
OPERA study

Patients after cardiothoracic surgery **with hypoxemia**


Stephan F et al, JAMA, 2017
BIPOP study group




Postoperative pulmonary complications



Postoperative pulmonary complications




Postoperative pulmonary complications



Postoperative pulmonary embolism

Thromboprophylaxis



- Increased **thrombotic risk** for the first **12 weeks** after surgery (especially in women)
- Thromboprophylaxis at least **10-14 days** after surgery
- High risk patients for VTE extensive duration for **4 weeks**
- Extending for up to **5 weeks** in orthopedic surgery patients

Quyatt J et al, ACCP Guidelines, Chest, 2012
Sweetland S et al, BMJ, 2009

A1: Each risk factor represents 1 point	B: Each risk factor represents 2 points
<ul style="list-style-type: none"> <input type="radio"/> Age 40–59 years <input type="radio"/> Minor surgery planned <input type="radio"/> History of prior major surgery <input type="radio"/> Varicose veins <input type="radio"/> History of inflammatory bowel disease <input type="radio"/> Swollen legs (current) <input type="radio"/> Obesity (BMI > 30) <input type="radio"/> Acute myocardial infarction (< 1 month) <input type="radio"/> Congestive heart failure (< 1 month) <input type="radio"/> Sepsis (< 1 month) <input type="radio"/> Serious lung disease incl. pneumonia (< 1 month) <input type="radio"/> Abnormal pulmonary function (chronic obstructive pulmonary disease) <input type="radio"/> Medical patient currently at bed rest <input type="radio"/> Leg plaster cast or brace <input type="radio"/> Central venous access <input type="radio"/> Blood transfusion (< 1 month) <input type="radio"/> Other risk factor/s _____ 	<ul style="list-style-type: none"> <input type="radio"/> Age 60–74 years <input type="radio"/> Major surgery (< 60 minutes)* <input type="radio"/> Arthroscopic surgery (> 60 minutes)* <input type="radio"/> Laparoscopic surgery (> 60 minutes)* <input type="radio"/> Previous malignancy <input type="radio"/> Morbid obesity (BMI > 40)
A2: For women only (each represents 1 point)	C: Each risk factor represents 3 points
<ul style="list-style-type: none"> <input type="radio"/> Oral contraceptives or hormone replacement therapy <input type="radio"/> Pregnancy or postpartum (< 1 month) <input type="radio"/> History of unexplained stillborn infant, recurrent spontaneous abortion (≥ 3), premature birth with toxemia of pregnancy or growth restricted infant 	<ul style="list-style-type: none"> <input type="radio"/> Age 75 years or more <input type="radio"/> Major surgery lasting 2–3 hours* <input type="radio"/> BMI > 50 (venous stasis syndrome) <input type="radio"/> History of SVT, DVT/PE <input type="radio"/> Family history of DVT/PE <input type="radio"/> Present cancer or chemotherapy <input type="radio"/> Present factor V Leiden <input type="radio"/> Positive prothrombin 20210A <input type="radio"/> Elevated serum homocysteine <input type="radio"/> Positive lupus anticoagulant <input type="radio"/> Elevated anticardiolipin antibodies <input type="radio"/> Heparin-induced thrombocytopenia (HIT) <input type="radio"/> Other thrombophilia-type _____
D: Each risk factor represents 5 points	
	<ul style="list-style-type: none"> <input type="radio"/> Elective major lower extremity arthroplasty <input type="radio"/> Hip, pelvis or leg fracture (< 1 month) <input type="radio"/> Stroke (< 1 month) <input type="radio"/> Multiple trauma (< 1 month) <input type="radio"/> Acute spinal cord injury (paralysis) (< 1 month) <input type="radio"/> Major surgery lasting over 3 hours*
Total risk factor score:	

**High risk for VTE
Caprini score ≥ 5**

Postoperative pulmonary embolism


Treatment




- Management dilemma – risk of thrombolysis?
- Recent surgery relative contraindication (except brain or spinal surgery, trauma)
- Major bleeding >50% within 1 week
- Major bleeding 20% in 1-2 weeks
- Significantly reduced bleeding risk 2 weeks after surgery



Thank you !



Postoperative respiratory failure V/Q relationship



Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients A Randomized Clinical Trial

Hernandez G, JAMA, 2016

JAMA | Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients A Randomized Clinical Trial

Hernandez G, JAMA, 2016

High risk patients

APACHE>12

Age>65

HF

COPD

BMI>30

>2 cormobidities

Difficult weaning


MV>7days

Airway patency


Deal of secretions

Post-extubation respiratory failure

Low risk



High risk



No. at risk

Conventional therapy	263	244	236	231
High-flow therapy	264	256	252	251

No. at risk

High-flow oxygen therapy	290	260	234	223
Noninvasive mechanical ventilation	314	279	269	253

Hernandez G, JAMA, 2016

Hernandez G, JAMA, 2016

